Animal Models of Lung Disease

  • Roberto Barrios
Part of the Molecular Pathology Library book series (MPLB, volume 2)


Animal models afford the opportunity for investigators to study the study the mechanisms of human disorders by experimentally manipulating a number of controlled variables. Experimental models can be arbitrarily divided into (a) spontaneous disease models, which are mutant animals that carry a disease similar to a human condition; (b) models obtained through genetic manipulation, in other words, gene-modified models including: transgenic and knock out animals and (c) chemically or physically induced changes. Researchers have to chose from a number of possibilities such as species and strain of animal, environment, and the genome to investigate the molecular interactions involved in the pathogenesis of many diseases.1 Experimental models also provide a unique opportunity to test potential therapeutic intervention. Well-developed animal models should share features with specific human disorders. Although the basic molecular biology terminology is covered in other chapters of this book, it is convenient to briefly review the basic technology for the development of transgenic mice.


Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Cystic Fibrosis Transmembrane Conductance Regulator Malignant Mesothelioma loxP Site 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kumar RK. Experimental models in pulmonary pathology. Pathology. 1995;27(2):130–132.CrossRefPubMedGoogle Scholar
  2. 2.
    Barlozzari T, et al. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol. 1985;134(4):2783–2789.PubMedGoogle Scholar
  3. 3.
    McCabe PM, et al. Animal models of disease. Physiol Behav. 2000;68(4):501–507.CrossRefPubMedGoogle Scholar
  4. 4.
    Brusselle GG, et al. Murine models of COPD. Pulm Pharmacol Ther. 2006;19:155–165.CrossRefPubMedGoogle Scholar
  5. 5.
    Paigen K. A miracle enough: the power of mice. Nat Med. 1995;1(3):215–220.CrossRefPubMedGoogle Scholar
  6. 6.
    Glasser SW, et al. Transgenic models for study of pulmonary development and disease. Am J Physiol. 1994;267(5 pt 1):L489–L497.PubMedGoogle Scholar
  7. 7.
    Ho YS. Transgenic models for the study of lung biology and disease. Am J Physiol. 1994;266(4 pt 1):L319–L353.PubMedGoogle Scholar
  8. 8.
    Shapiro SD. Animal models for COPD. Chest. 2000;117(5 suppl 1):223S–227S.CrossRefPubMedGoogle Scholar
  9. 9.
    Shapiro SD. Animal models for chronic obstructive pulmonary disease: age of klotho and marlboro mice. Am J Respir Cell Mol Biol. 2000;22(1):4–7.PubMedGoogle Scholar
  10. 10.
    Lucey EC. Experimental emphysema. Clin Chest Med. 1983;4(3):389–403.PubMedGoogle Scholar
  11. 11.
    Snider GL, Lucey EC, Stone PJ. Animal models of emphysema. Am Rev Respir Dis. 1986;133(1):149–169.PubMedGoogle Scholar
  12. 12.
    Guerassimov A, et al. The development of emphysema in cigarette smoke-exposed mice is strain dependent. Am J Respir Crit Care Med. 2004;170(9):974–980.CrossRefPubMedGoogle Scholar
  13. 13.
    Bartalesi B, et al. Different lung responses to cigarette smoke in two strains of mice sensitive to oxidants. Eur Respir J. 2005;25(1):15–22.CrossRefPubMedGoogle Scholar
  14. 14.
    Valentine R, et al. Morphological and biochemical features of elastase-induced emphysema in strain A/J mice. Toxicol Appl Pharmacol. 1983;68(3):451–461.CrossRefPubMedGoogle Scholar
  15. 15.
    Gross P, et al. Experimental emphysema: its production with papain in normal and silicotic rats. Arch Environ Health. 1965;11:50–58.PubMedGoogle Scholar
  16. 16.
    Shiomi T, et al. Emphysematous changes are caused by degradation of type III collagen in transgenic mice expressing MMP-1. Exp Lung Res. 2003;29(1):1–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Foronjy RF, et al. Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol. 2003;284(5):L727–L737.PubMedGoogle Scholar
  18. 18.
    Zheng T, et al. Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema. J Clin Invest. 2000;106(9):1081–1093.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med. 2000;192(11):1587–1600.CrossRefPubMedGoogle Scholar
  20. 20.
    Elwood W, et al. Characterization of allergen-induced bronchial hyperresponsiveness and airway inflammation in actively sensitized brown-Norway rats. J Allergy Clin Immunol. 1991;88(6):951–960.CrossRefPubMedGoogle Scholar
  21. 21.
    Nagai H, et al Effect of anti-IL-5 monoclonal antibody on allergic bronchial eosinophilia and airway hyperresponsiveness in mice. Life Sci. 1993;53(15):PL243–PL247.CrossRefPubMedGoogle Scholar
  22. 22.
    Renz H, et al. Specific V beta T cell subsets mediate the immediate hypersensitivity response to ragweed allergen. J Immunol. 1993;151(4):1907–1917.PubMedGoogle Scholar
  23. 23.
    Kung TT, et al. Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol. 1994;105(1):83–90.CrossRefPubMedGoogle Scholar
  24. 24.
    Chavez J, et al. Interactions between leukotriene C4 and interleukin 13 signaling pathways in a mouse model of airway disease. Arch Pathol Lab Med. 2006;130(4):440–446.PubMedGoogle Scholar
  25. 25.
    Kerem B, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073–1080.CrossRefPubMedGoogle Scholar
  26. 26.
    Buchwald M, Tsui LC, Riordan JR. The search for the cystic fibrosis gene. Am J Physiol. 1989;257(2 pt 1):L47–L52.PubMedGoogle Scholar
  27. 27.
    Riordan JR, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989;245(4922):1066–1073.CrossRefPubMedGoogle Scholar
  28. 28.
    Rommens JM, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989;245(4922):1059–1065.CrossRefPubMedGoogle Scholar
  29. 29.
    Snouwaert JN, et al. An animal model for cystic fibrosis made by gene targeting. Science. 1992;257(5073):1083–1088.CrossRefPubMedGoogle Scholar
  30. 30.
    Davidson DJ, Rolfe M. Mouse models of cystic fibrosis. Trends Genet. 2001;17(10):S29–S37.CrossRefPubMedGoogle Scholar
  31. 31.
    Guilbault C, et al. Cystic fibrosis mouse models. Am J Respir Cell Mol Biol. 2007;36(1):1–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Frizzell RA, Pilewski JM. Finally, mice with CF lung disease. Nat Med. 2004;10(5):452–454.CrossRefPubMedGoogle Scholar
  33. 33.
    Mall M, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med. 2004;10(5):487–493.CrossRefPubMedGoogle Scholar
  34. 34.
    Fleischman RW, et al. Bleomycin-induced interstitial pneumonia in dogs. Thorax. 1971;26(6):675–682.CrossRefPubMedGoogle Scholar
  35. 35.
    Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol. 1974;77(2):185–197.PubMedGoogle Scholar
  36. 36.
    Adamson IY, Bowden DH. Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung. Am J Pathol. 1979;96(2):531–544.PubMedGoogle Scholar
  37. 37.
    Snider GL, Hayes JA, Korthy AL. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: pathology and stereology. Am Rev Respir Dis. 1978;117(6):1099–1108.PubMedGoogle Scholar
  38. 38.
    Borzone G, et al. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7):1648–1653.PubMedGoogle Scholar
  39. 39.
    Popenoe D. Effects of paraquat aerosol on mouse lung. Arch Pathol Lab Med. 1979;103(7):331–334.PubMedGoogle Scholar
  40. 40.
    Yoshida M, et al A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci U S A 1995;92(21):9570–9574.CrossRefPubMedGoogle Scholar
  41. 41.
    Katsuma S, et al. Molecular monitoring of bleomycin-induced pulmonary fibrosis by cDNA microarray-based gene expression profiling. Biochem Biophys Res Commun. 2001;288(4):747–751.CrossRefPubMedGoogle Scholar
  42. 42.
    Brantley JG, et al. Cux-1 transgenic mice develop glomerulosclerosis and interstitial fibrosis. Kidney Int. 2003;63(4):1240–1248.CrossRefPubMedGoogle Scholar
  43. 43.
    Driessens J, et al The urethane-induced experimental pulmonary adenoma in the mouse. I. Histological study. C R Seances Soc Biol Fil. 1962;156:655–ʿ657.PubMedGoogle Scholar
  44. 44.
    Mirvish SS. The carcinogenic action and metabolism of urethan and N-hydroxyurethan. Adv Cancer Res. 1968;11:1–42.CrossRefPubMedGoogle Scholar
  45. 45.
    Brooks RE. Pulmonary adenoma of strain A mice: an electron microscopic study. J Natl Cancer Inst. 1968;41(3):719–742.PubMedGoogle Scholar
  46. 46.
    Gargus JL, Paynter OE, Reese WH Jr. Utilization of newborn mice in the bioassay of chemical carcinogens. Toxicol Appl Pharmacol. 1969;15(3):552–559.CrossRefPubMedGoogle Scholar
  47. 47.
    Shabad LM. Dose-response studies in experimentally induced lung tumours. Environ Res. 1971;4(4):305–315.CrossRefPubMedGoogle Scholar
  48. 48.
    Snyder C, et al. Urethan-induced pulmonary adenoma as a tool for the study of surfactant biosynthesis. Cancer Res. 1973;33(10):2437–2443.PubMedGoogle Scholar
  49. 49.
    Cazorla M, et al. Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. Mol Carcinog. 1998;21(4):251–260.CrossRefPubMedGoogle Scholar
  50. 50.
    Lin L, et al. Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res. 1998;24(4):481–497.CrossRefPubMedGoogle Scholar
  51. 51.
    Avanzo JL, Mesnil M, Hernandez-Blazquez FJ, et al. Altered expression of connexins in urethane-induced mouse lung adenomas. Life Sci. 2006;79:2202–2208.CrossRefPubMedGoogle Scholar
  52. 52.
    Umemura T, et al. Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modification by butylhydroxytoluene. Cancer Lett. 1999;145(1-2):101–106.CrossRefPubMedGoogle Scholar
  53. 53.
    Furth PA. SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Dev Biol Stand. 1998;94:281–287.PubMedGoogle Scholar
  54. 54.
    Wikenheiser KA, et al Simian virus 40 large T antigen directed by transcriptional elements of the human surfactant protein C gene produces pulmonary adenocarcinomas in transgenic mice. Cancer Res. 1992;52(19):5342–5352.PubMedGoogle Scholar
  55. 55.
    Wikenheiser KA, Whitsett JA. Tumor progression and cellular differentiation of pulmonary adenocarcinomas in SV40 large T antigen transgenic mice. Am J Respir Cell Mol Biol. 1997;16(6):713–723.PubMedGoogle Scholar
  56. 56.
    Kwak I, Tsai SY, DeMayo FJ. Genetically engineered mouse models for lung cancer. Annu Rev Physiol. 2004;66:647–663.CrossRefPubMedGoogle Scholar
  57. 57.
    Zhao B, et al. Transgenic mouse models for lung cancer. Exp Lung Res. 2000;26(8):567–579.CrossRefPubMedGoogle Scholar
  58. 58.
    Albanese C, et al. Recent advances in inducible expression in transgenic mice. Semin Cell Dev Biol. 2002;13(2):129–141.CrossRefPubMedGoogle Scholar
  59. 59.
    Argmann C, Dierich A, Auwrex J. Current Protocols in Molecular Biology. New York: Wiley; 2006 [unit 29.A.1].Google Scholar
  60. 60.
    Matsuda I, Aiba A. Receptor knock-out and knock-in strategies. Methods Mol Biol. 2004;259:379–390.PubMedGoogle Scholar
  61. 61.
    Sato Y, et al. Establishment of Cre/LoxP recombination system in transgenic rats. Biochem Biophys Res Commun. 2004;319(4):1197–1202.CrossRefPubMedGoogle Scholar
  62. 62.
    Altomare DA, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005;65(18):8090–8095.CrossRefPubMedGoogle Scholar
  63. 63.
    Altomare DA, et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005;24(40):6080–6089.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Roberto Barrios
    • 1
  1. 1.Department of Pathology and Laboratory MedicineWeill Medical College of Cornell UniversityNew YorkUSA

Personalised recommendations